In genetically engineered mice with pancreatic cancer, ENO1 DNA vaccine elicits antitumor immune responses by decreasing numbers of myeloid-derived suppressor cells and T-regulatory cells and increasing T-helper 1 and 17 responses to prolong survival (16). This evidence concerns the gene ENO1 and familial pancreatic carcinoma.